BGI Genomics Hits Day Low of CNY 37.18 Amid Price Pressure

BGI Genomics Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 3.78% on May 22, 2026. The stock reached an intraday low of CNY 37.18, reflecting ongoing challenges in its market performance. Over the past week, BGI Genomics has seen a significant decrease of 8.15%, while its performance over the last month shows a decline of 5.88%. The company has faced a stark contrast to the China Shanghai Composite, which has shown a positive performance of 0.87% today. In terms of long-term performance, BGI Genomics has struggled, with a year-to-date decline of 17.48% and a staggering 68.63% drop over the past five years. The company's financial metrics indicate a concerning trend, with net sales decreasing at an annual rate of 13.07% and operating profit plummeting by 177.01% over the last five years. As BGI Genomics navigates these challenges, its current market position reflects a complex landscape within the biotechnology industry.